Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
BMC Neurology|November 3, 2021
The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature reviewAlison M Deighton, Linda A Harris, Karissa Johnston, et al.
Journal of Cardiac Failure|August 17, 2004
The relationship between health perception and utility in heart failure patients in a clinical trial: results from an OVERTURE substudyEdward P Havranek, Teresa A Simon, Gilbert L'Italien, et al.
Clinical Therapeutics|May 19, 2009
Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysisEdward Kim, Ross Maclean, Diane Ammerman, et al.
Cerebellum (London, England)|June 12, 2024
Psychometric Validation of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) in Patients With Spinocerebellar AtaxiaMichele Potashman, Evan Popoff, Lauren Powell, et al.
Cephalalgia : an International Journal of Headache|April 25, 2024
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraineRobert Croop, Gary Berman, David Kudrow, et al.
Headache|May 22, 2021
Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraineEvan Popoff, Karissa Johnston, Robert Croop, et al.
Value in Health Regional Issues|April 29, 2018
Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back ProjectionPhilip McEwan, Thomas Ward, Chien-Jen Chen, et al.
Advances in Therapy|August 29, 2021
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving RimegepantKarissa M Johnston, Gilbert L'Italien, Evan Popoff, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 21, 2021
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysisKarissa Johnston, Evan Popoff, Alison Deighton, et al.
Advances in Therapy|November 23, 2022
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)Lauren C Powell, Gilbert L'Italien, Evan Popoff, et al.
Pageof 7